


TRPM8 antagonist 2

Cat. No.:	HY-112430		
CAS No.:	259674-19-6		
Molecular Formula:	C ₂₆ H ₂₆ N ₂ O ₂		
Molecular Weight:	398.5		
Target:	TRP Channel		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 160 mg/mL (401.51 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.5094 mL	12.5471 mL	25.0941 mL
		5 mM	0.5019 mL	2.5094 mL	5.0188 mL
10 mM		0.2509 mL	1.2547 mL	2.5094 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.67 mg/mL (6.70 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.67 mg/mL (6.70 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.67 mg/mL (6.70 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	TRPM8 antagonist 2 is a potent and selective TRPM8 antagonist, with an IC ₅₀ of 0.2 nM, used in the research of neuropathic pain syndromes.
IC₅₀ & Target	IC ₅₀ : 0.2 nM (TRPM8) ^[1]
In Vitro	TRPM8 antagonist 2 (Compound 14) is a potent and selective TRPM8 antagonist, with an IC ₅₀ of 0.2 nM, used in the research of neuropathic pain syndromes. TRPM8 antagonist 2 potently inhibits menthol-induced increase in intracellular Ca ²⁺ levels

in Ca²⁺ fluorimetric assays in HEK293 cells stably expressing the rat isoform of TRPM8 channels (IC₅₀, 40 nM)^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TRPM8 antagonist 2 (1, 10, and 30 mg/kg, s.c.) shows a marked, dose-dependent antinociceptive activity, and inhibits wet-dog shakes (WDS)-like cold hypersensitivity in mice by 63% at 30 mg/kg. In addition, TRPM8 antagonist 2 (0.1 and 1 µg, s.c.) attenuates Oxaliplatin (OXP)-induced cold allodynia in mice^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]

Mice^[1]
Icilin, a TRPM8 agonist, is dissolved in 20% DMSO and 1% Tween 80 in distilled water and injected intraperitoneally (i.p.) in a volume of 10 mL/kg. Each animal is acclimatized for 30 min for two consecutive days before icilin administration. TRPM8 antagonist 2 (compound 14) stock is prepared in DMSO and diluted in saline for injections. Gabapentin is dissolved in saline and administered s.c. at the dose of 25 mg/kg 60 min prior to icilin injection. Control animals receive the vehicle injection^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bertamino A, et al. Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity. J Med Chem. 2018 Jul 10. doi: 10.1021/acs.jmedchem.8b00545.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA